440 U.S. Highway 22 East
119 articles with Amneal Pharmaceuticals
AMNEAL INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Amneal Pharmaceuticals, Inc. - AMRX
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Amneal Pharmaceuticals, Inc. (NYSE: AMRX).
Amneal Pharmaceuticals, Inc. (NYSE:AMRX) today announced that members of management will participate in a fireside chat at the RBC Capital Markets Global Healthcare Conference in New York on Tuesday, May 21, 2019 at 11:00 a.m. Eastern Time.
AMNEAL INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Amneal Pharmaceuticals, Inc. To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Amneal Pharmaceuticals, Inc..
Amneal Pharmaceuticals, Inc. announced its results today for the first quarter ended March 31, 2019.
The Company will host a conference call and live webcast with the investment community at 8:30 a.m., Eastern Time on May 9, 2019.
4/5/2019Pharma, biotech and life science companies strengthen leadership teams, with news from Vertex, Arvinas, Provention, Enterome, and more.
Amneal Pharmaceuticals, Inc. (NYSE: AMRX), today announced that it has entered into an agreement with Zentiva Group a.s., under which Zentiva has acquired Creo Pharmaceuticals Ltd., a subsidiary of Amneal that operates the company's commercial operations in the United Kingdom.
Company's first approval and launch of a transdermal product
Amneal Pharmaceuticals, Inc. announced its results today for the fourth quarter and year ended December 31, 2018.
Amneal Pharmaceuticals, Inc. announced that the Company will release its fourth quarter and full year 2018 financial results on Thursday, February 28, 2019, prior to the open of the U.S. financial markets.
Branning Brings Expertise in Leading Change Management Across Complex and Rapidly Evolving Organizations
The Company is planning to commercialize its Rivastigmine Transdermal System shortly.
The U.S. Food and Drug Administration (FDA) approved Bridgewater, NJ-based Amneal Pharmaceuticals’ generic version of Novartis’ Exelon Patch (Rivastigmine Transdermal System) for dementia related to Alzheimer’s and Parkinson’s diseases.
Amneal Pharmaceuticals, Inc. announced that it has appointed David A. Buchen to the newly expanded role of Senior Vice President, Chief Legal Officer and Corporate Secretary, reporting to President and Chief Executive Officer Robert Stewart
Amneal Pharmaceuticals (NYSE: AMRX) today announced that members of management will present at the 37th Annual J.P. Morgan Healthcare Conference at the Westin St. Francis in San Francisco on Tuesday, January 8, 2019.
Piper Jaffray Healthcare Conference in New York, NY, on Tuesday, November 27, 2018 at 1:00 p.m. ET.
Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into an agreement with Amneal Pharmaceuticals, Inc. (Amneal) with regard to Levothyroxine Sodium Tablets USP.
Amneal Completes Transition Agreement With Lannett Company To Begin Commercialization Of Levothyroxine On December 1st
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced that it has completed a transition agreement with Lannett Company.
Net Revenue of $476 Million; Diluted EPS of $0.05; Adjusted Diluted EPS of $0.28
Expiration Dates for Certain Lots of Generic Adrenaclick® Epinephrine Injection, USP Auto-Injector Extended to 20 Months
Impax Laboratories LLC today announced that in collaboration with the U.S. Food and Drug Administration (FDA), the Company is extending the expiration dates for certain lots of its epinephrine injection, USP auto-injector, 0.15 mg and 0.3 mg, the authorized generic of Adrenaclick®.